EF Hutton Reiterates Buy on VolitionRX, Maintains $4.5 Price Target
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Tim Moore has reiterated a Buy rating on VolitionRX (AMEX:VNRX) and maintained a price target of $4.5 for the company's stock.
January 02, 2024 | 6:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
EF Hutton analyst Tim Moore reaffirmed a Buy rating on VolitionRX with a price target of $4.5, indicating a positive outlook on the stock.
The reiteration of a Buy rating by a reputable analyst like Tim Moore from EF Hutton can instill confidence in investors and potentially lead to a positive short term impact on VolitionRX's stock price. The maintained price target of $4.5 suggests that the analyst sees the stock as undervalued at its current price, which could encourage investment and drive up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100